Study volunteers play a critical role in the discovery of new treatments, therapies, ways of diagnosing different diseases, and the advancement of medicine. Our team is dedicated to providing with all information available to help you make an informed decision as to whether or not joining a study or trial is right for yourself or a loved one. See below for a list of our currently enrolling clinical trials.
​
We are always adding new trials to the list, sign up for our e-mail list to be notified about upcoming trials.
​
By signing up for our email list, you agree to receive emails about our enrolling studies. You may unsubscribe at any time.
​
​
Currently Enrolling Clinical Trials
Please fill out our Interest Form below if you are interested in learning more about our trials.
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease.
The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain.
The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study.
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.